770-71-8

Applied Filters:

Keyword:'770-71-8'

Showing 1-1 of 1 result for "770-71-8" within Papers

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

Fred Saad et al.

The Lancet. Oncology, 16(3), 338-348 (2015-02-24)

Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. In this phase 3, double-blind

Page 1 of 1